GERMANTOWN, Md., April 20, 2020 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I/II trial for Precigen’s PRGN-2009, a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse™ platform designed to activate the immune system to recognize and target HPV+ solid tumors. HPV+ cancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer.
{iframe}https://www.biospace.com/article/releases/precigen-announces-clearance-of-ind-to-initiate-phase-i-ii-study-for-first-in-class-prgn-2009-adenoverse-immunotherapy-to-treat-hpv-positive-hpv-solid-tumors/{/iframe}